EX-10.7





 Exhibit 10.7 

CONSULTING AGREEMENT 
 This Consulting
Agreement (the “Agreement”) is made effective as of March 13, 2013 (the “Effective Date”), by and between Vedantra Pharmaceuticals Inc., a Delaware corporation, with its principal place of business being One Kendall Square,
Building 1400 West, Suite 14303 Cambridge, MA. 02139 (the “Company”) and Danforth Advisors, LLC, a Massachusetts limited liability corporation, with its principal place of business being 91 Middle Road, Southborough, MA 01772
(“Danforth”). The Company and Danforth are herein sometimes referred to individually as a “Party” and collectively as the “Parties.” 

WHEREAS, the Company possesses know-how and proprietary technology related to the acquisition,
financing and development of therapeutics, particularly in oncology; and 
 WHEREAS, Danforth has expertise in financial and corporate
operations and strategy; and 
 WHEREAS, Danforth desires to serve as an independent consultant for the purpose of providing the Company
with certain strategic and financial advice and support services, as more fully described in Exhibit A attached hereto, (the “Services”); and 

WHEREAS, the Company wishes to engage Danforth on the terms and conditions set forth herein. 

NOW THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which are hereby acknowledged,
the Parties agree and covenant as follows. 
  

	1.	 Services of Consultant. Danforth will assist the Company with matters relating to the Services. The
Services are more fully described in Exhibit A attached hereto. Danforth and the Company will review the Services on a monthly basis to prioritize and implement the tasks listed on Exhibit A. Danforth will work with the Company
according to a monthly budget that will be agreed upon in advance of each month and not exceeded without prior approval of the Company. 


  

	2.	 Compensation for Services. In full consideration of Danforth’s full, prompt and faithful
performance of the Services, the Company shall compensate Danforth a consulting fee more fully described in Exhibit A (the “Consulting Fee”). Danforth shall, from time to time, but not more frequently than once per calendar month
invoice the Company for Services rendered and such invoice will be paid upon fifteen (15) days of receipt. Each month the Parties shall evaluate jointly the current fee structure and scope of Services. Fees shall be subject to an annual 3%
increase effective on each anniversary of the Agreement. Upon termination of this Agreement pursuant to Section 3, no compensation or benefits of any kind as described in this Section 2 shall be payable or issuable to Danforth after the
effective date of such termination. In addition, the Company will reimburse Danforth for reasonable out-of-pocket business expenses, including but not limited to travel
and parking, incurred by Danforth in performing the Services hereunder, upon submission by Danforth of supporting documentation reasonably acceptable to the Company. Such accrued expenses in any given three (3) month period shall not exceed one
thousand dollars ($1,000) unless submitted to the Company for its prior written approval. 















	3.	 Term and Termination. The term of this Agreement will commence on the Effective Date and will continue
through the anniversary of such date in the next calendar year (the “Term”). This Agreement will automatically renew for an additional one (1) year period as mutually agreed to by the parties. This Agreement may be terminated by
either Party hereto: (a) with Cause (as defined below), upon written notice to the other Party; or (b) without cause upon thirty (30) days prior written notice to the other Party. For purposes of this Section 3, “Cause”
shall include: (i) a breach of the terms of this Agreement which is not cured within thirty (30) days of written notice of such default or (ii) the commission of any act of fraud, embezzlement or deliberate disregard of a rule or
policy of the Company. 


  

	4.	 Time Commitment. Danforth will devote such time to perform the Services under this Agreement as may
reasonably be required. 


  

	5.	 Place of Performance. Danforth will perform the Services at such locations upon which the Company and
Danforth may mutually agree. Danforth will not, without the prior written consent of the Company, perform any of the Services at any facility or in any manner that might give anyone other than the Company any rights to or allow for disclosure of any
Confidential Information (as defined below). 


  

	6.	 Compliance with Policies and Guidelines. Danforth will perform the Services in accordance with all rules
or policies adopted by the Company that the Company discloses in writing to Danforth. 


  

	7.	 Confidential Information. Danforth acknowledges and agrees that during the course of performing the
Services, the Company may furnish, disclose or make available to Danforth information, including, but not limited to, material, compilations, data, formulae, models, patent disclosures, procedures, processes, business plans, projections, protocols,
results of experimentation and testing, specifications, strategies and techniques, and all tangible and intangible embodiments thereof of any kind whatsoever (including, but not limited to, any apparatus, biological or chemical materials, animals,
cells, compositions, documents, drawings, machinery, patent applications, records and reports), which is owned or controlled by the Company and is marked or designated as confidential at the time of disclosure or is of a type that is customarily
considered to be confidential information (collectively the “Confidential Information”). Danforth acknowledges that the Confidential Information or any part thereof is the exclusive property of the Company and shall not be disclosed to any
third party without first obtaining the written consent of the Company. Danforth further agrees to take all practical steps to ensure that the Confidential Information, and any part thereof, shall not be disclosed or issued to its affiliates, agents
or employees, except on like terms of confidentiality. The above provisions of confidentiality shall apply for a period of five (5) years. 



  
 2 














	8.	 Intellectual Property. Danforth agrees that all ideas, inventions, discoveries, creations, manuscripts,
properties, innovations, improvements, know-how, inventions, designs, developments, apparatus, techniques, methods, and formulae that Danforth conceives, makes, develops or improves as a result of performing
the Services, whether or not reduced to practice and whether or not patentable, alone or in conjunction with any other party and whether or not at the request or upon the suggestion of the Company (all of the foregoing being hereinafter collectively
referred to as the “Inventions”), shall be the sole and exclusive property of the Company. Danforth hereby agrees in consideration of the Company’s agreement to engage Danforth and pay compensation for the Services rendered to the
Company and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged that Danforth shall not, without the prior written consent of the Company, directly or indirectly, consult for, or become an employee
of, any company which conducts business in the Field of Interest anywhere in the world. As used herein, the term “Field of Interest” shall mean the research, development, manufacture and/or sale of the products resulting from the
Company’s technology. The limitations on competition contained in this Section 7 shall continue during the time that Danforth performs any Services for the Company (whether as a consultant, employee or otherwise), and for a period of three
(3) months following the termination of any such Services that Danforth performs for the Company. If any part of this section should be determined by a court of competent jurisdiction to be unreasonable in duration, geographic area, or scope,
then this Section 7 is intended to and shall extend only for such period of time, in such area and with respect to such activity as is determined to be reasonable. Except as expressly provided herein, nothing in this Agreement shall preclude
Danforth from consulting for or being employed by any other person or entity. 


  

	9.	 Non Solicitation. All personnel representing Danforth are employees or contracted agents of Danforth. As
such, they are obligated to provide the Services to the Company and are obligated to Danforth under confidentiality, non-compete, and non-solicitation agreements.
Accordingly, they are not retainable as employees or contractors by the Company and the Company hereby agrees not to solicit, hire or retain their services for so long as they are employees or contracted agents of Danforth and for one (1) year
thereafter. Should the Company violate this restriction, it agrees to pay Danforth liquidated damages equal to fifteen thousand ($15,000) dollars for each Danforth employee or contracted agent hired by the Company in violation of this Agreement,
plus Danforth’s reasonable attorneys’ fees and costs incurred in enforcing this agreement should the Company fail or refuse to pay the liquidated damages amount in full within thirty (30) days following its violation.



  

	10.	 Placement Services. In the event that Danforth refers a potential employee to the Company and that
individual is hired, Danforth shall receive a fee equal to fifteen percent (15%) of the employee’s starting annual base salary. This fee is due and owing whether an individual is hired, directly or indirectly on a permanent basis or on a
contract or consulting basis by the Company, as a result of Danforth’s efforts within one (1) year of the date applicant(s) are submitted to the Company. Such payment is due within thirty (30) days of the employee’s start date.




  
 3 














	11.	 No Implied Warranty. Except for any express warranties stated herein, the Services are provided on an
“as is” basis, and the Company disclaims any and all other warranties, conditions, or representations (express, implied, oral or written), relating to the Services or any part thereof. Further, in performing the Services Danforth is not
engaged to disclose illegal acts, including fraud or defalcations, which may have taken place. The foregoing notwithstanding, Danforth will promptly notify the Company or, if appropriate, the Board of Directors, if Danforth becomes aware of any such
illegal acts during the performance of the Services. Because the Services do not constitute an examination in accordance with standards established by the American Institute of Certified Public Accountants (the “AICPA”), Danforth is
precluded from expressing an opinion as to whether financial statements provided by the Company are in conformity with generally accepted accounting principles or any other standards or guidelines promulgated by the AICPA, or whether the underlying
financial and other data provide a reasonable basis for the statements. 


  

	12.	 Indemnification. Each Party hereto agrees to indemnify and hold the other Party hereto, its directors,
officers, agents and employees harmless against any claim based upon circumstances alleged to be inconsistent with such representations and/or warranties contained in this Agreement. Further, the Company shall indemnify and hold harmless Danforth
and any of its subcontractors against any claims, losses, damages or liabilities (or actions in respect thereof) that arise out of or are based on the Services performed hereunder, except for any such claims, losses, damages or liabilities arising
out of the gross negligence or willful misconduct of Danforth or any of its subcontractors. The Company will endeavor to add Consultant and any applicable subcontractor to its insurance policies as additional insured’s. 



 

	13.	 Independent Contractor. Danforth is not, nor shall Danforth be deemed to be at any time during the term
of this Agreement, an employee of the Company, and therefore Danforth shall not be entitled to any benefits provided by the Company to its employees, if applicable. Danforth’s status and relationship with the Company shall be that of an
independent contractor and consultant. Danforth shall not state or imply, directly or indirectly, that Danforth is empowered to bind the Company without the Company’s prior written consent. Nothing herein shall create, expressly or by
implication, a partnership, joint venture or other association between the parties. Danforth will be solely responsible for payment of all charges and taxes arising from its relationship to the Company as a consultant. 



 

	14.	 Records. Upon termination of Danforth’s relationship with the Company, Danforth shall deliver to
the Company any property or Confidential Information of the Company relating to the Services which may be in its possession including products, project plans, materials, memoranda, notes, records, reports, laboratory notebooks, or other documents or
photocopies and any such information stored using electronic medium. 



  
 4 














	15.	 Notices. Any notice under this Agreement shall be in writing (except in the case of verbal
communications, emails and teleconferences updating either Party as to the status of work hereunder) and shall be deemed delivered upon personal delivery, one day after being sent via a reputable nationwide overnight courier service or two days
after deposit in the. Notices under this Agreement shall be sent to the following representatives of the Parties: 


 If to
the Company: 
 Name:      William Koster 

Title:        Chairman 

Address:  One Kendall Square 

  Building 1400 West, Suite 14303 

  Cambridge, MA. 02139 

Phone:      (617) 945-2077 

E-mail:    meagen.boyle@vedantra.com 

If to Danforth: 

Name:      Gregg Beloff 

Title:        Managing Director 

Address:  91 Middle Road 

  Southborough, MA 01772 

Phone:     617-686-7679 

E-mail:    gbeloff(adanforthadvisors.com 

 

	16.	 Assignment and Successors. This Agreement may not be assigned by a Party without the consent of the
other which shall not be unreasonably withheld, except that each Party may assign this Agreement and the rights, obligations and interests of such Party, in whole or in part, to any of its Affiliates, to any purchaser of all or substantially all of
its assets or to any successor corporation resulting from any merger or consolidation of such Party with or into such corporation. 


  

	17.	 Force Majeure. Neither Party shall be liable for failure of or delay in performing obligations set forth
in this Agreement, and neither shall be deemed in breach of its obligations, if such failure or delay is due to natural disasters or any causes beyond the reasonable control of either Party. In event of such force majeure, the Party affected thereby
shall use reasonable efforts to cure or overcome the same and resume performance of its obligations hereunder. 


  

	18.	 Headings. The Section headings are intended for convenience of reference only and are not intended to be
a part of or to affect the meaning or interpretation of this Agreement. 


  

	19.	 Integration; Severability. This Agreement is the sole agreement with respect to the subject matter
hereof and shall supersede all other agreements and understandings between the Parties with respect to the same. If any provision of this Agreement is or becomes invalid or is ruled invalid by any court of competent jurisdiction or is deemed
unenforceable, it is the intention of the Parties that the remainder of the Agreement shall not be affected. 



  
 5 














	20.	 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
Commonwealth of Massachusetts, excluding choice of law principles. The Parties agree that any action or proceeding arising out of or related in any way to this Agreement shall be brought solely in a Federal or State court of competent jurisdiction
sitting in the Commonwealth of Massachusetts. 


  

	21.	 Counterparts. This Agreement may be executed in counterparts, each of which will be deemed an original,
but all of which together will constitute one agreement. 


 If you are in agreement with the foregoing, please sign where indicated below,
whereupon this Agreement shall become effective as of the Effective Date. 
  

									
	DANFORTH ADVISORS	  		  	VEDANTRA PHARMACEUTICS INC.
					
	By:	  	 /s/ Daniel Geffken
	  		  	By:	  	 /s/ William H. Koster

	Print Name: Daniel Geffken	  		  	Print Name: William H. Koster
	Title: Managing Director	  		  	Title: Chairman
	Date: 3/13/14	  		  	Date: March 13, 2014


  
 6 













 EXHIBIT A 

Description of Services and Schedule of Fees 

Danforth will perform mutually agreed to finance and accounting functions which are necessary to support the: (i) management and operations of
Company’s business; and (ii) the terms of Company’s investor and other business agreements. Some specific accounting / finance activities included in the services are as follows: 

Accounting and Controller Services 
 Some specific
controller activities included in the services are as follows: 
 Accounting 

 

	 	•	 	 Management of day-today accounting functions 



 

	 	•	 	 Review, summarization and analysis of historical expenses 



 

	 	•	 	 Cash reconciliation and cash usage 



 

	 	•	 	 Cost analysis 


  

	 	•	 	 A/P 


  

	 	•	 	 Prep US GAAP compliant internal financial statements 



 

	 	•	 	 Quarterly investor reporting 



 

	 	•	 	 Monthly payroll/benefits administration 



 

	 	•	 	 Scope of exposures (adequate insurance for property and casualty, E&O, D&O coverage)



 Forecasting 
  

	 	•	 	 On-going forecast and budget tracking 



 

	 	•	 	 Budget to actual 


  

	 	•	 	 Annual operating budget 



 

	 	•	 	 Cash runway analysis 



Audit/Tax 
  

	 	•	 	 Annual audit preparation and management of audit 



 

	 	•	 	 Coordination and planning of corporate tax return preparation 



 

	 	•	 	 Sales and use, payroll and franchise tax oversight 



Other 
  

	 	•	 	 Vendor management (including all contracts, suppliers, W-9s and issuing
1099s at year end) 


  

	 	•	 	 Financial policies, procedures and controls review 














 CFO Services 

Some specific corporate finance activities included in the services are as follows: 

Planning 
  

	 	•	 	 Strategic business planning 



 

	 	•	 	 Cost reduction planning 



 

	 	•	 	 Corporate and business development advisory work 



 

	 	•	 	 Assistance in fundraising 



 

	 	•	 	 Business development / licensing support 



 

	 	•	 	 Financial modeling, planning and analysis 



 

	 	•	 	 Strategic opportunity assessment 



 

	 	•	 	 Board, Audit, Compensation, and Corporate Governance committee meeting preparation, support and attendance



 Other 
  

	 	•	 	 Stock option plan management 



 

	 	•	 	 Capitalization table management 



 

	 	•	 	 Audit / maintenance of corporate records (minute book, stock records, option agreements) 



 

	 	•	 	 Management and evaluation of 409A valuations 



Schedule and Fees: 
 Controller: Cheryl McCarthy:
$130/hour 
 Financial Planning & Analysis (if necessary for program management): $170/hour 

CFO: Daniel Geffken, as necessary: $260/hour 
 Danforth shall,
from time to time, but not more frequently than once per calendar month invoice the Company for Services rendered and such invoice will be paid upon fifteen (15) days of receipt. 












 AMENDMENT NO. 1 TO CONSULTING AGREEMENT 

This Amendment No. 1 to Consulting Agreement (“Amendment”) is made as of April 30, 2014 (“Effective Date”), by
and between Danforth Advisors, LLC (“Consultant”), a corporation located at 91 Middle Road, Southborough, MA 01722 and Vedantra Pharmaceuticals, Inc., a Delaware corporation (“Company”), located at One Kendall Square, Building
1400 West, Suite 14303, Cambridge, MA 02139. Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors, LLC and the Company dated as of March 13, 2014
(“Agreement”). 
 WHEREAS, Consultant is engaged by the Company under the terms and conditions of the Agreement and the
parties hereto desire to revise the terms of the Agreement on the terms and conditions set forth more fully herein; and 
 WHEREAS,
the Company and Consultant mutually desire to amend the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the premises
and the mutual covenants and agreements herein contained and for the other good and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: 

1. Exhibit A – Description of Services and Schedule of Fees, is hereby amended by inserting a new Consulting Service offered by Consultant
after the description under the CFO Services section: 
 “Contract Management Services 

Some specific contract manager activities included in the services are as follows: 

	 	•	 	 Review contracts management system and ensure company agreements are organized; 



 

	 	•	 	 Develop index to company agreements, as approved by Company; 



 

	 	•	 	 Draft, review and finalize company agreements as necessary; 



 

	 	•	 	 Assist Company outside counsel with review and negotiation of company contracts; 



 

	 	•	 	 Additional special projects as may be requested by Company.” 



2. Exhibit A – Description of Services and Schedule of Fees, is hereby amended by inserting the following new entry under the Schedule
of Fees Section: 
 “Contracts Manager: Ellen Wing: $130/hour” 

3. Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified and shall remain in full force and
effect. 












 4. This Amendment may be executed in one or more counterparts, each of which shall be
considered an original instrument, but all of which shall be considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. 

IN WITNESS WHEREOF, this Amendment has been executed by Vedantra Pharmaceuticals, Inc. and Danforth Advisors, LLC to be effective as of the date first above
written. 
  

					
	DANFORTH ADVISORS, LLC	  		  	VEDANTRA PHARMACEUTICALS, INC.
			
	 /s/ Daniel Geffken
	  		  	 /s/ William H. Koster

	Name	  		  	Name
			
	 Daniel Geffken
	  		  	 William H. Koster

	Print Name	  		  	Print Name
			
	 Managing Director
	  		  	 Chairman

	Title	  		  	Title
			
	 5-1-14
	  		  	 May 1, 2014

	Date	  		  	Date













 AMENDMENT NO. 2 TO CONSULTING AGREEMENT 

This Amendment No. 2 to Consulting Agreement (“Amendment”) is made as of January 31, 2016 (“Effective Date”), by
and between Vedantra Pharmaceuticals, Inc. with a principal place of business being One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA 02139(“Company”) and Danforth Advisors, LLC (“Consultant”), with a principal
place of business being 91 Middle Road, Southborough, MA 01722 (“Danforth”). Capitalized terms use but not defined herein shall have the respective meaning set forth in the Consulting Agreement by and between Danforth Advisors and the
Company dated as of March 13, 2013. 
 WHEREAS, Consultant is engaged by the company under the terms and conditions of the
Consulting Agreement and the parties hereto desire to revise the terms of the Consulting Agreement on the terms and conditions set forth more fully herein; and 

WHEREAS, the Company and Consultant mutually desire to amend the scope of the Agreement. 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained and for the other good and
valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: 
  

	 	1.	 Section 3. Term and Termination is hereby modified to extend the term of the Agreement until
March 31, 2017. 


  

	 	2.	 Exhibit A – 1, attached hereto is added to the Agreement in its entirety. 



 

	 	3.	 Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified and shall
remain in full force and effect. 


 This Amendment may be executed in one or more counterparts, each of which shall be considered an
original instrument, but all of which shall be considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. 

IN WITNESS WHEREOF, this Amendment has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above
written. 
 ******** 













					
	DANFORTH ADVISORS, INC.	  		  	VEDANTA PHARMACEUTICAL INC.
			
	 /s/ Christine Boehing
	  		  	 /s/ Julian Adams

	Name	  		  	Name
			
	 Christine Boehing
	  		  	 Julian Adams

	Print Name	  		  	Print Name
			
	 Director of Operations
	  		  	 Executive Chairman

	Title	  		  	Title
			
	 2/15/16
	  		  	  

	Date:	  		  	Date:













 EXHIBIT A -2 

Amendment of the Description of Services and Schedule of Fees 

Danforth will perform the mutually agreed to finance and accounting functions which are necessary to support the management and operations of the Company, as
outlined in Exhibit A of the Consulting Agreement by and between Danforth Advisors and the Company dated as of March 13, 2013. 
 Fees:

 The section entitled Fees in Exhibit A and Amendment 1 dated as of March 13, 2014 of the Consulting Agreement by and between Danforth
Advisors and the Company dated March 13, 2013 is hereby replaced in its entirety by the following: 
 Danforth shall be paid at the following rates per
hour, for actual Services rendered as follows: 
  

					
	 CFO: Daniel Geffken
	  	RATE: $	275	 
	 Controller: Cheryl McCarthy
	  	RATE: $	140	 
	 Contracts Manager: Ellen Wing
	  	RATE: $	140	 













 AMENDMENT NO. 3 TO CONSULTING AGREEMENT 

This Amendment No. 3 to Consulting Agreement (“Amendment No. 3”) is made as of July 10, 2019 (“Effective Date of
Amendment No.3”), by and between Elicio Therapeutics, formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA 02139
(“Company”) and Danforth Advisors, LLC, with a principal place of business being 91 Middle Road, Southborough, MA 01772 (“Consultant”). Capitalized terms use but not defined herein shall have the respective meaning set forth in
the Consulting Agreement by and between Consultant and the Company dated as of March 13, 2013 (“Agreement”). 

WHEREAS, Consultant is engaged by the company under the terms and conditions of the Consulting Agreement and the parties hereto desire
to revise the terms of the Consulting Agreement on the terms and conditions set forth more fully herein; and 
 WHEREAS, the Company
and Consultant mutually desire to amend the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the premises and the
mutual covenants and agreements herein contained and for the other good and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: 

 

	 	1.	 Section 3. Term and Termination of the Agreement is replaced in its entirety with the following.



 Section 3. Term and Termination. The term of this Agreement will commence on the Effective
Date of the Agreement and will continue until such time as either party has given notice of termination pursuant to this paragraph 3 (the “Term”). This Agreement may be terminated by either Party hereto: (a) with Cause (as defined
below), upon thirty (30) days prior written notice to the other Party; or (b) without cause upon sixty (60) days prior written notice to the other Party. For purposes of this Section 3, “Cause” shall include: (i) a
breach of the terms of this Agreement which is not cured within thirty (30) days of written notice of such default or (ii) the commission of any act of fraud, embezzlement or deliberate disregard of a rule or policy of the Company. 

 

	 	2.	 Except as specifically provided for in this Amendment No. 3, the terms of the Agreement shall be
unmodified and shall remain in full force and effect. For avoidance of doubt the Agreement remained in effect between March 13, 2013 and the Effective Date of Amendment No.3. 



This Amendment No. 3 may be executed in one or more counterparts, each of which shall be considered an original instrument, but all of which shall be
considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. 

IN WITNESS WHEREOF, this Amendment No.3 has been executed by the Company and Danforth Advisors, LLC to be effective as of the date first above
written. 













					
	DANFORTH ADVISORS, INC.	  		  	ELICIO THERAPEUTICS, INC.
			
	 /s/ Gregg Beloff
	  		  	 /s/ Robert Connelly

	Name	  		  	Name
			
	 Gregg Beloff
	  		  	 Robert Connelly

	Print Name	  		  	Print Name
			
	 Managing Director
	  		  	 CEO

	Title	  		  	Title
			
	 7/10/19
	  		  	 07/11/2019

	Date	  		  	Date













 AMENDMENT NO. 4 TO CONSULTING AGREEMENT 

This Amendment No. 4 to Consulting Agreement (“Amendment No. 4”) is made as of December 18, 2020, by and between
Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA 02139 (“Company”) and Danforth
Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). Capitalized terms used but not defined herein shall have the respective meaning set
forth in the Consulting Agreement by and between Danforth and the Company dated as of March 13, 2013 (“Agreement”). 

WHEREAS, Danforth is engaged by the company under the terms and conditions of the Agreement and the parties hereto desire to revise the
terms of the Agreement on the terms and conditions set forth more fully herein; and 
 WHEREAS, the Company and Danforth mutually
desire to amend the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and
agreements herein contained and for the other good and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: 
  

	 	1.	 Exhibit A is hereby modified to add the services of various Danforth employees to perform the Services required
by the Company as further described thereon and to revise the Schedule and Fees as further specified and attached hereto in Exhibit A-2 which is added to the Agreement in its entirety. 



 

	 	2.	 Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified and shall
remain in full force and effect. 


 This Amendment No. 4 may be executed in one or more counterparts, each of which
shall be considered an original instrument, but all of which shall be considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. 












 IN WITNESS WHEREOF, this Amendment No. 4 has been executed by the Company and Danforth
Advisors, LLC to be effective as of the date first above written. 
  

					
	 DANFORTH ADVISORS, LLC
	  		  	 Elicio Therapeutics, Inc. 

			
	 /s/ Chris Connors
	  		  	 /s/ Robert T. Connelly

	Name	  		  	Name
			
	 Chris Connors
	  		  	 Robert T. Connelly 

			
	 President
	  		  	 CEO

	Title	  		  	Title
			
	 1/30/2021
	  		  	 1/7/21

	Date	  		  	Date













 Exhibit A-2 

Description of Services and Schedule of Fees 
  

	 	•	 	 Deliverable: Initial text, revisions and improvements leading to a completed business section (not
including IP, strategic partnerships, competition and government regulation) including participation in an organizational meeting and as many drafting sessions are necessary, typically up to two drafting sessions. 



 

	 	•	 	 Compensation: Compensation will be the sum of $200,000 payable in three increments. The “First
Increment” is to be $50,000. to be paid within seven calendar days of the Effective Date to Danforth. $100,000 of the compensation, the “Second Increment,” will be invoiced upon delivery of an interim draft of the S-1 business section. The remaining $50,000 of the compensation, the “Third Increment,” will be invoiced upon the earlier of these two events: (1) handoff of the draft of the S-1 business section to client’s attorney or (2) the three month anniversary of the Effective Date of this Amendment. In no case will the Second and Third Increments be invoiced later than the three-month
anniversary of the Effective Date. Each of the Second and Third Increments of the compensation will be due within 30 days of receipt of the applicable invoice. 














 AMENDMENT NO. 5 TO CONSULTING AGREEMENT 

This Amendment No. 5 to Consulting Agreement (“Amendment No. 4”) is made as of February 1, 2021, by and between
Elicio Therapeutics Inc., formerly operating under the name of Vedantra Pharmaceuticals, Inc., with a principal place of business being One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA 02139 (“Company”) and Danforth
Advisors, LLC, a Massachusetts limited liability company, with a principal place of business being 91 Middle Road, Southborough, MA 01772 (“Danforth”). Capitalized terms used but not defined herein shall have the respective meaning set
forth in the Consulting Agreement by and between Danforth and the Company dated as of March 13, 2013 (“Agreement”). 

WHEREAS, Danforth is engaged by the company under the terms and conditions of the Agreement and the parties hereto desire to revise the
terms of the Agreement on the terms and conditions set forth more fully herein; and 
 WHEREAS, the Company and Danforth mutually
desire to amend the scope of the Agreement. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants and
agreements herein contained and for the other good and valuable consideration, receipt of which is hereby acknowledge, the parties hereby agree as follows: 
  

	 	1.	 Exhibit A is hereby modified to add the services of various Danforth employees to perform the Services required
by the Company as further described thereon and to revise the Schedule and Fees as further specified and attached hereto in Exhibit A-2 which is added to the Agreement in its entirety. 



 

	 	2.	 Except as specifically provided for in this Amendment, the terms of the Agreement shall be unmodified and shall
remain in full force and effect. 


 This Amendment No. 5 may be executed in one or more counterparts, each of which
shall be considered an original instrument, but all of which shall be considered one and the same Amendment, and shall become binding when one or more counterparts have been signed by each of the parties and delivered to the other. 












 IN WITNESS WHEREOF, this Amendment No. 5 has been executed by the Company and Danforth
Advisors, LLC to be effective as of the date first above written. 
  

					
	 DANFORTH ADVISORS, LLC
	 		  	 Elicio Therapeutics, Inc. 

			
	 /s/ Chris Connors
	 		  	 /s/ Robert Connelly

	Name	 		  	Name
			
	 Chris Connors
	 		  	 Robert Connelly 

			
	 President
	 		  	 Chief Executive Officer

		 		  	Title
			
	 2/1/2021
	 		  	 February 1st, 2021

	Date	 		  	Date













 Exhibit A-2 

Description of Services and Schedule of Fees 

Danforth will perform mutually agreed to finance and accounting functions which are necessary to support the management and operations of the Company, certain
of which are set forth below: 
  

					
	 Role
	  	 Name
	  	 Hourly Rate

	 Senior Advisor
	  	 Daniel Geffken
	  	 $450/hour

			
	 Managing Director
	  	 Lance Thibault
	  	 $400/hour

			
	 CFO
	  	 Heather Kiessling
	  	 $375/hour

			
	 Director
	  	 Charlie Darder
	  	 $275/hour

			
	 Senior Manager
	  	 Cheryl McCarthy
	  	 $225/hour